Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05IPO
|
|||
| Former ID |
DCL000732
|
|||
| Drug Name |
BTS-79018
|
|||
| Synonyms |
CHEMBL418854; SCHEMBL6767394; BDBM50079939; L018296
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Terminated | [1] | |
| Company |
Abbott
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H27ClN2O3
|
|||
| Canonical SMILES |
COC1=CC=CC=C1N2CCC(CC2)CNCC3COC4=C(O3)C=C(C=C4)Cl
|
|||
| InChI |
1S/C22H27ClN2O3/c1-26-20-5-3-2-4-19(20)25-10-8-16(9-11-25)13-24-14-18-15-27-21-7-6-17(23)12-22(21)28-18/h2-7,12,16,18,24H,8-11,13-15H2,1H3/t18-/m0/s1
|
|||
| InChIKey |
QHLRKDSRGUZHSH-SFHVURJKSA-N
|
|||
| CAS Number |
CAS 246517-66-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Binder | [1] |
| Dopamine D3 receptor (D3R) | Target Info | Binder | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Dopaminergic synapse | ||||
| cAMP signaling pathway | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Dopamine receptors | |||
| G alpha (i) signalling events | ||||
| Serotonin receptors | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Nicotine Activity on Dopaminergic Neurons | ||||
| GPCRs, Other | ||||
| Serotonin HTR1 Group and FOS Pathway | ||||
| SIDS Susceptibility Pathways | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.